Hikma launches levothyroxine sodium injection

Hikma is offering levothyroxine sodium injection in ready-to-use vials in a 100 mcg/ml dose.

Levothyroxine sodium is an important medicine used in hospitals for the treatment of myxedema coma.

The medication has a market value of approximately $52 million in the 12 months ending September 2022, according to IQVIA.

[Read more: Hikma to acquire Custopharm]

Riad Mishlawi, president of injectables at Hikma, said, “We are pleased to launch levothyroxine sodium Injection in a more concentrated, ready-to-use formulation. This launch, which came to us through the Custopharm acquisition, broadens the choice of medicines available to hospitals, helping us to ensure that we are providing affordable and accessible medicines to those in need. We are committed to expanding our portfolio of essential medicines that serve the growing needs of U.S. medical professionals.”